A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
University of Colorado, Denver
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Eisai Inc.
Yale University
M.D. Anderson Cancer Center